Organon & Co. (NYSE:OGN) Upgraded by TD Cowen to Hold Rating

Organon & Co. (NYSE:OGN) was upgraded by analysts at TD Cowen to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Separately, Evercore ISI upgraded Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Organon & Co. has an average rating of “Hold” and an average target price of $21.33.

Organon & Co. Stock Performance

Shares of Organon & Co. stock opened at $15.77 on Wednesday. The firm has a market capitalization of $4.06 billion, a price-to-earnings ratio of 3.13, a PEG ratio of 0.86 and a beta of 0.76. Organon & Co. has a one year low of $13.87 and a one year high of $23.10. The business has a 50-day simple moving average of $15.32 and a 200 day simple moving average of $18.24. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). The business had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The business’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.78 EPS. On average, research analysts anticipate that Organon & Co. will post 3.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of OGN. Mercer Global Advisors Inc. ADV increased its position in shares of Organon & Co. by 1.8% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 31,086 shares of the company’s stock valued at $674,000 after purchasing an additional 546 shares during the last quarter. Sippican Capital Advisors grew its position in Organon & Co. by 4.3% during the third quarter. Sippican Capital Advisors now owns 15,230 shares of the company’s stock valued at $291,000 after buying an additional 627 shares during the period. Commerce Bank increased its holdings in Organon & Co. by 5.5% during the third quarter. Commerce Bank now owns 12,168 shares of the company’s stock worth $233,000 after buying an additional 637 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its position in Organon & Co. by 32.4% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after acquiring an additional 672 shares during the period. Finally, Graypoint LLC raised its position in Organon & Co. by 6.2% in the third quarter. Graypoint LLC now owns 14,555 shares of the company’s stock worth $278,000 after acquiring an additional 853 shares during the period. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.